Logotype for Longeveron Inc

Longeveron (LGVN) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Longeveron Inc

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Laromestrocel remains the lead investigational therapy across four potential indications; strategic and financing alternatives, including a potential business combination, are under review with Lucid Capital Markets as advisor.

  • ELPIS II missed its primary HLHS efficacy endpoint; an updated analysis found fewer adjudicated events and a statistically significant MACE difference, and an FDA meeting was requested to discuss next steps.

Financial highlights

  • Q3 2026 revenue was $115K vs. $137K YoY; gross profit was $71K vs. $125K, with lower contract manufacturing revenue contributing to the decline.

  • Q3 operating loss was $7.2M vs. $7.3M; net loss was $6.1M vs. $7.2M, reflecting $1.0M of XPRIZE Healthspan award income and lower G&A expense.

  • 9M 2026 revenue was $800K vs. $834K; operating loss was $18.1M vs. $17.9M and net loss was $16.9M vs. $17.3M.

  • 9M operating cash use was $12.7M; financing provided $15.5M, lifting cash by $2.6M to $7.2M at September 30, 2026.

Outlook and guidance

  • Cash and cash equivalents of $7.2M were expected to fund operations into Q1 2027 under current plans and cash-conservation measures; additional capital will be needed to advance development.

  • Strategic alternatives may include a partnership or investment, additional financing, a sale or merger, or a business combination; no definitive timeline or assured outcome was established.

  • HLHS next steps depend on FDA review of ELPIS II; proposed AD Phase 2/3 and pediatric DCM trial plans depend on partnerships, funding and strategic review.

  • Forecasts show insufficient cash to meet minimum expenditure commitments for one year from financial-statement issuance; substantial doubt exists about the ability to continue as a going concern.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Longeveron